b'Results Results (contd)Patients and Previous Medication Use A total of 1581 patients with AD and 1 claim for ruxolitinib cream were includedTreatment Patterns(Table 1) During the 6-month period after the index date (follow-up period), mean In the 6-month period before the index date (pre-index period), 57.4% of patients(SD) number of ruxolitinib cream fills was 1.6 (1.07)had received topical AD therapy, and 36.2% received systemic therapy43.8% (n=692) of patients received ruxolitinib cream monotherapy 72.0% (n=1138) did not receive a new class of AD treatment after the Table 1. Baselineinitiation creamDemographic Initiation of ruxolitinib cream was associated with reductions in the use ofand Clinical other topical therapies (Figure 2)Characteristics Among Ruxolitinib Cream Users Figure 2. Topical Treatment Pattern for AD Before and After Ruxolitinib Cream Use The use of oral corticosteroids decreased from 20.9% (n=330) in the pre-index period to 15.5% (n=245) in the follow-up periodAD, atopic dermatitis; ADHD, attention-deficit/hyperactivity Mean cumulative prednisone-equivalent dose among all patients disorder; ASCVD, atheroscleroticdecreased by 31.5% (77.2 to 52.9 mg; Figure 3)cardiovascular disease; PDE-4, phosphodiesterase-4.*Comorbidities occurring in 2.5% of patients at baseline.Patients could have received more than one baseline AD therapy. Immunosuppressants included azathioprine, mycophenolate mofetil, cyclosporine, or methotrexate.'